NO922138L - Fremstilling av rekombinant human interleukin-1-inhibitor - Google Patents

Fremstilling av rekombinant human interleukin-1-inhibitor

Info

Publication number
NO922138L
NO922138L NO92922138A NO922138A NO922138L NO 922138 L NO922138 L NO 922138L NO 92922138 A NO92922138 A NO 92922138A NO 922138 A NO922138 A NO 922138A NO 922138 L NO922138 L NO 922138L
Authority
NO
Norway
Prior art keywords
inhibitor
preparation
recombinant human
human interleukin
disclosed
Prior art date
Application number
NO92922138A
Other languages
English (en)
Other versions
NO922138D0 (no
NO305290B1 (no
Inventor
Robert Hageman
Stephen P Eisenberg
David Dripps
Ronald Evans
Henryk Cudny
Robert C Thompson
Original Assignee
Synergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synergen Inc filed Critical Synergen Inc
Publication of NO922138L publication Critical patent/NO922138L/no
Publication of NO922138D0 publication Critical patent/NO922138D0/no
Publication of NO305290B1 publication Critical patent/NO305290B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
NO922138A 1989-11-29 1992-05-29 FremgangsmÕte til fremstilling av rekombinant human interleukin-1-inhibitor NO305290B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44265289A 1989-11-29 1989-11-29
PCT/US1990/006979 WO1991008285A1 (en) 1989-11-29 1990-11-29 Production of recombinant human interleukin-1 inhibitor

Publications (3)

Publication Number Publication Date
NO922138L true NO922138L (no) 1992-05-29
NO922138D0 NO922138D0 (no) 1992-05-29
NO305290B1 NO305290B1 (no) 1999-05-03

Family

ID=23757611

Family Applications (1)

Application Number Title Priority Date Filing Date
NO922138A NO305290B1 (no) 1989-11-29 1992-05-29 FremgangsmÕte til fremstilling av rekombinant human interleukin-1-inhibitor

Country Status (17)

Country Link
US (1) US5453490A (no)
EP (1) EP0502956B1 (no)
JP (1) JP3014007B2 (no)
KR (1) KR0182819B1 (no)
AT (1) ATE152172T1 (no)
AU (1) AU651955B2 (no)
BR (1) BR9007883A (no)
CA (1) CA2068320C (no)
DE (1) DE69030582T2 (no)
DK (1) DK0502956T3 (no)
ES (1) ES2103305T3 (no)
FI (1) FI104733B (no)
GR (1) GR3024031T3 (no)
HK (1) HK1006856A1 (no)
HU (1) HUT64582A (no)
NO (1) NO305290B1 (no)
WO (1) WO1991008285A1 (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5861476A (en) * 1994-02-02 1999-01-19 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5880096A (en) * 1994-02-02 1999-03-09 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5786331A (en) * 1994-02-02 1998-07-28 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5608035A (en) * 1994-02-02 1997-03-04 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5837495A (en) * 1994-10-13 1998-11-17 Applied Research Systems Ars Holding N.V. DNA encoding interleukin-1 antagonist
US5981713A (en) * 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
IT1270662B (it) * 1994-10-13 1997-05-07 Applied Research Systems Antagonista della interleuchina-1
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
JP4771563B2 (ja) 1996-12-06 2011-09-14 アムジエン・インコーポレーテツド Ｉｌ−１媒介疾患を処置するためにｉｌ−１インヒビターを使用する組合せ療法
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US6013253A (en) * 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
MXPA04000134A (es) 2001-06-26 2005-06-06 Abgenix Inc Anticuerpos para ligandos de osteoprotegerina.
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
BRPI0314038B8 (pt) 2002-09-06 2021-05-25 Amgen Inc anticorpo humano isolado, molécula de ácido nucleico isolada, vetor, uso de um anticorpo, e, composição farmacêutica
AU2005231822B2 (en) 2004-04-02 2011-07-21 Swedish Orphan Biovitrum Ab (Publ) Methods of reducing aggregation of IL-1ra
AR056806A1 (es) 2005-11-14 2007-10-24 Amgen Inc Moleculas quimericas de anticuerpo rankl- pth/ pthrp
US20070248653A1 (en) * 2006-04-20 2007-10-25 Cochrum Kent C Hemostatic compositions and methods for controlling bleeding
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
US10105441B2 (en) * 2007-08-16 2018-10-23 The Schepens Eye Research Institute, Inc. Method for inhibiting or reducing dry eye disease by IL-1Ra
US8323635B2 (en) 2007-11-14 2012-12-04 General Regeneratives, Ltd. Methods of using interleukin-1 receptor antagonist as a myeloprotective agent
EP2567692B1 (en) 2008-02-27 2016-04-06 Biomet Biologics, LLC Use of a device for obtaining interleukin-1 receptor antagonist rich solutions
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
CN101690801B (zh) 2009-10-26 2012-08-01 上海交通大学 白细胞介素-1受体拮抗剂的用途及其药物组合物
HUE063115T2 (hu) 2010-07-29 2023-12-28 Buzzard Pharmaceuticals AB Kiméra I-es típusú IL-1 receptor antagonisták
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
RU2014107743A (ru) * 2011-07-29 2015-09-10 Илэвэн Байотерапьютикс, Инк. Очищенные белки
WO2013170636A1 (zh) 2012-05-18 2013-11-21 爱德迪安（北京）生物技术有限公司 用于糖尿病治疗的蛋白、蛋白缀合物及其应用
US20140308239A1 (en) 2013-03-13 2014-10-16 Eleven Biotherapeutics, Inc. Chimeric cytokine formulations for ocular delivery
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
EP3068438A1 (en) 2013-11-11 2016-09-21 Ascendis Pharma Relaxin Division A/S Relaxin prodrugs
EP3074507B1 (en) 2013-11-26 2022-01-05 Biomet Biologics, LLC Methods of mediating macrophage phenotypes
US20160000936A1 (en) 2014-06-10 2016-01-07 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
US10041044B2 (en) 2016-07-29 2018-08-07 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
US11285196B2 (en) 2017-03-13 2022-03-29 Eslam Abbas Baseuny Multivalent biologic constructs for inducing a therapeutic modulation of cellular response and uses thereof
EP3836954A1 (en) 2018-08-13 2021-06-23 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU633471B2 (en) * 1987-08-26 1993-02-04 Biogen Idec Ma Inc. Biological materials, processes for producing biological materials and for using such materials in therapy
KR0148009B1 (ko) * 1988-05-27 1998-08-01 그래고리 비. 아보트 인터루킨-1 억제제
US5075222A (en) * 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
AU7683391A (en) * 1990-04-27 1991-11-27 Upjohn Company, The Modified interleukin-1 inhibitors
WO1991017249A1 (en) * 1990-05-01 1991-11-14 Cetus Corporation Interleukin-1 antagonist and uses thereof

Also Published As

Publication number Publication date
CA2068320C (en) 2000-10-17
CA2068320A1 (en) 1991-05-30
FI104733B (fi) 2000-03-31
KR0182819B1 (en) 1999-04-01
GR3024031T3 (en) 1997-10-31
US5453490A (en) 1995-09-26
NO922138D0 (no) 1992-05-29
ATE152172T1 (de) 1997-05-15
FI922434A (fi) 1992-05-27
ES2103305T3 (es) 1997-09-16
JP3014007B2 (ja) 2000-02-28
DE69030582D1 (de) 1997-05-28
JPH05503007A (ja) 1993-05-27
HU9201777D0 (en) 1992-12-28
DK0502956T3 (da) 1997-10-20
DE69030582T2 (de) 1998-06-25
EP0502956A1 (en) 1992-09-16
EP0502956A4 (en) 1992-12-09
BR9007883A (pt) 1992-09-29
AU6900791A (en) 1991-06-26
EP0502956B1 (en) 1997-04-23
FI922434A0 (fi) 1992-05-27
KR920703792A (ko) 1992-12-18
AU651955B2 (en) 1994-08-11
HK1006856A1 (en) 1999-03-19
WO1991008285A1 (en) 1991-06-13
NO305290B1 (no) 1999-05-03
HUT64582A (en) 1994-01-28

Similar Documents

Publication Publication Date Title
NO922138L (no) Fremstilling av rekombinant human interleukin-1-inhibitor
IT8048102A0 (it) Procedimento di preparazione di un idrolisato di proteine purificato
PT822199E (pt) Polipeptidos monopegilados no terminal-n e metodo para a sua preparacao
ITMI920569A0 (it) Procedimento per la fabbricazione di tastiere
IT8867187A0 (it) Procedimento per la fabbricazione di cemento
AU7817387A (en) Purification of recombinant tumor necrosis factor
NO902071L (no) Fremgangsmaate og mellomprodukter for fremstilling av oksoftalazinyl-eddiksyrer og analoger derav.
IT1218065B (it) Procedimento per pa preparazione di 1,2,5,6,9,10 esabromociclododecano
IT8947842A0 (it) Procedimento per la produzione di r(+) amminocarnitina e s(-) amminocarnitina
EP0378824A3 (en) Use of omega-3-fatty acids as anticachexia agents
IT1229522B (it) Procedimento per la preparazione di acido n fosfonometiliminodiacetico.
IT9020860A0 (it) Procedimento per la depurazione fine di gas
IT8467785A0 (it) Procedimento per la produzione di tirosina
IT8719420A0 (it) Purificazione di interleuchina-1umana ricombinante.
AU7422387A (en) Tumor necrosis factor alpha as treatment for infectious diseases
AU2885689A (en) Novel proteins derived from human alpha2-plasmin inhibitor orproteins similar thereto
IT1231506B (it) Procedimento per la purificazione di polieteri polioli.
IT1247508B (it) Composizioni farmaceutiche contenenti l'estere 4-(2 metilamminoetil)- 1,2- fenilenicodell`acido 2-metilpropanoico per il trattamento della neurootticopatia glaucomatosa
IT1226147B (it) Processo per la preparazione di perfluoro (2 bromoetilviniletere).
FR2639346B1 (fr) Procede de production d'(alpha)-olefines
IT8819919A0 (it) Procedimento perfezionato per laproduzione di componenti ceramici.
IT1174139B (it) Procentimento per la fabbricazione di magnesia refrattaria
IT1217906B (it) Procedimento per la realizzazione di fogli autoadesivi
AU588493B2 (en) Treatment of diseases caused by viruses
CS719388A1 (en) Derivatives of thioallophanic acid

Legal Events

Date Code Title Description
MK1K Patent expired